FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667002> ?p ?o ?g. }

• W4385667002 endingPage "e68516d0" @default.
• W4385667002 startingPage "e68516d0" @default.
• W4385667002 abstract "Topic: 2. Acute lymphoblastic leukemia - Clinical Background: The standard of care in patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is BCR::ABL1 tyrosine kinase inhibitors (TKIs) in combination with chemotherapy or steroids. Treated with first- or second-generation TKIs, patients eventually progress due to emergence of resistance. Multiple studies have reported promising minimal residual disease (MRD) negativity (neg) rates and survival outcomes with ponatinib in combination with chemotherapy or chemotherapy-free regimens. Aims: PhALLCON (NCT03589326), the first randomized study comparing TKIs in patients with Ph+ ALL, evaluates ponatinib versus imatinib in combination with reduced-intensity chemotherapy. Methods: This phase 3 open-label study randomized newly diagnosed Ph+ ALL adult patients 2:1 to receive ponatinib (30 mg once daily [QD]) or imatinib (600 mg QD) with reduced-intensity chemotherapy through end of induction (EOI), consolidation, and post-consolidation. After post-consolidation, patients received single-agent ponatinib or imatinib until disease progression or unacceptable toxicity. The composite primary endpoint was MRD-neg (BCR::ABL1 ≤0.01%) complete remission (CR) for 4 weeks at EOI. Event-free survival (EFS: any-cause death, failure to achieve CR by EOI, relapse from CR) was a key secondary endpoint. Results: A total of 245 pts were randomized to ponatinib (n=164) or imatinib (n=81); median age was 54 years (37% ≥60 years). At data cutoff (Aug 2022), 78 patients (ponatinib vs imatinib: 42% vs 12%) were on study treatment; the top 3 reasons for discontinuation were hematopoietic stem cell transplantation (30% vs 37%), adverse events (12% vs 12%), and lack of efficacy (7% vs 26%). Median follow-up was 20 months vs 18 months (ponatinib vs imatinib). The primary endpoint was met (Table), with a significantly higher MRD-neg CR rate at EOI for ponatinib vs imatinib (34% vs 17%; P=0.0021). Additionally, MRD-neg rate regardless of CR at EOI was significantly higher for ponatinib vs imatinib (43% vs 21%; P=0.0017). Median duration of MRD-neg and time to treatment failure were not reached for ponatinib and were 20.9 months and 21.9 months, respectively, for imatinib. EFS data were not mature; however, the median EFS was reached in imatinib and not in ponatinib, with a trend toward improvement (hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.39–1.10). The treatment-emergent adverse event (TEAE) rates (any-grade and Grade 3/4/5) were comparable between treatment arms. Most common any-grade hematologic TEAEs were anemia (ponatinib 72%, imatinib 67%) and platelet count decrease (ponatinib 68%, imatinib 69%). The most common Grade 3/4 nonhematologic TEAEs were headache (ponatinib and imatinib 43%) and nausea (ponatinib 35%, imatinib 50%). Incidence of arterial occlusive events (AOEs) were infrequent and similar between the arms (Table). Summary/Conclusion: Ponatinib was superior to imatinib in combination with reduced-intensity chemotherapy in the front-line setting for patients with Ph+ ALL, with a significantly higher MRD-neg CR rate at EOI. Ponatinib was associated with deeper and more durable responses, with a trend toward improved EFS and comparable safety vs imatinib.Keywords: Ph+ ALL" @default.
• W4385667002 created "2023-08-09" @default.
• W4385667002 creator A5003682435 @default.
• W4385667002 creator A5006561610 @default.
• W4385667002 creator A5027778281 @default.
• W4385667002 creator A5030945111 @default.
• W4385667002 creator A5034614925 @default.
• W4385667002 creator A5036874214 @default.
• W4385667002 creator A5038004259 @default.
• W4385667002 creator A5038660651 @default.
• W4385667002 creator A5040369089 @default.
• W4385667002 creator A5040755016 @default.
• W4385667002 creator A5044624520 @default.
• W4385667002 creator A5049385583 @default.
• W4385667002 creator A5049910941 @default.
• W4385667002 creator A5049967785 @default.
• W4385667002 creator A5051969814 @default.
• W4385667002 creator A5052564121 @default.
• W4385667002 creator A5057465699 @default.
• W4385667002 creator A5065265065 @default.
• W4385667002 creator A5069675532 @default.
• W4385667002 creator A5078047769 @default.
• W4385667002 creator A5084354003 @default.
• W4385667002 creator A5090435894 @default.
• W4385667002 date "2023-08-01" @default.
• W4385667002 modified "2023-10-17" @default.
• W4385667002 title "S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL" @default.
• W4385667002 doi "https://doi.org/10.1097/01.hs9.0000967352.68516.d0" @default.
• W4385667002 hasPublicationYear "2023" @default.
• W4385667002 type Work @default.
• W4385667002 citedByCount "0" @default.
• W4385667002 crossrefType "journal-article" @default.
• W4385667002 hasAuthorship W4385667002A5003682435 @default.
• W4385667002 hasAuthorship W4385667002A5006561610 @default.
• W4385667002 hasAuthorship W4385667002A5027778281 @default.
• W4385667002 hasAuthorship W4385667002A5030945111 @default.
• W4385667002 hasAuthorship W4385667002A5034614925 @default.
• W4385667002 hasAuthorship W4385667002A5036874214 @default.
• W4385667002 hasAuthorship W4385667002A5038004259 @default.
• W4385667002 hasAuthorship W4385667002A5038660651 @default.
• W4385667002 hasAuthorship W4385667002A5040369089 @default.
• W4385667002 hasAuthorship W4385667002A5040755016 @default.
• W4385667002 hasAuthorship W4385667002A5044624520 @default.
• W4385667002 hasAuthorship W4385667002A5049385583 @default.
• W4385667002 hasAuthorship W4385667002A5049910941 @default.
• W4385667002 hasAuthorship W4385667002A5049967785 @default.
• W4385667002 hasAuthorship W4385667002A5051969814 @default.
• W4385667002 hasAuthorship W4385667002A5052564121 @default.
• W4385667002 hasAuthorship W4385667002A5057465699 @default.
• W4385667002 hasAuthorship W4385667002A5065265065 @default.
• W4385667002 hasAuthorship W4385667002A5069675532 @default.
• W4385667002 hasAuthorship W4385667002A5078047769 @default.
• W4385667002 hasAuthorship W4385667002A5084354003 @default.
• W4385667002 hasAuthorship W4385667002A5090435894 @default.
• W4385667002 hasBestOaLocation W43856670021 @default.
• W4385667002 hasConcept C126322002 @default.
• W4385667002 hasConcept C143998085 @default.
• W4385667002 hasConcept C197934379 @default.
• W4385667002 hasConcept C203092338 @default.
• W4385667002 hasConcept C2777408962 @default.
• W4385667002 hasConcept C2777583451 @default.
• W4385667002 hasConcept C2778715236 @default.
• W4385667002 hasConcept C2778729363 @default.
• W4385667002 hasConcept C2779536868 @default.
• W4385667002 hasConcept C2780381907 @default.
• W4385667002 hasConcept C2911091166 @default.
• W4385667002 hasConcept C535046627 @default.
• W4385667002 hasConcept C71924100 @default.
• W4385667002 hasConceptScore W4385667002C126322002 @default.
• W4385667002 hasConceptScore W4385667002C143998085 @default.
• W4385667002 hasConceptScore W4385667002C197934379 @default.
• W4385667002 hasConceptScore W4385667002C203092338 @default.
• W4385667002 hasConceptScore W4385667002C2777408962 @default.
• W4385667002 hasConceptScore W4385667002C2777583451 @default.
• W4385667002 hasConceptScore W4385667002C2778715236 @default.
• W4385667002 hasConceptScore W4385667002C2778729363 @default.
• W4385667002 hasConceptScore W4385667002C2779536868 @default.
• W4385667002 hasConceptScore W4385667002C2780381907 @default.
• W4385667002 hasConceptScore W4385667002C2911091166 @default.
• W4385667002 hasConceptScore W4385667002C535046627 @default.
• W4385667002 hasConceptScore W4385667002C71924100 @default.
• W4385667002 hasIssue "S3" @default.
• W4385667002 hasLocation W43856670021 @default.
• W4385667002 hasLocation W43856670022 @default.
• W4385667002 hasOpenAccess W4385667002 @default.
• W4385667002 hasPrimaryLocation W43856670021 @default.
• W4385667002 hasRelatedWork W2119900325 @default.
• W4385667002 hasRelatedWork W2418956447 @default.
• W4385667002 hasRelatedWork W2474810070 @default.
• W4385667002 hasRelatedWork W2948371802 @default.
• W4385667002 hasRelatedWork W2953325897 @default.
• W4385667002 hasRelatedWork W3036978401 @default.
• W4385667002 hasRelatedWork W4224037798 @default.
• W4385667002 hasRelatedWork W4230002713 @default.
• W4385667002 hasRelatedWork W4280598799 @default.
• W4385667002 hasRelatedWork W4283741924 @default.
• W4385667002 hasVolume "7" @default.
• W4385667002 isParatext "false" @default.

• next